Research ExplorerPublicationsA phase I study of recombinant human interleukin-21 (rIL-21)...

A phase I study of recombinant human interleukin-21 (rIL-21) in combination with sunitinib in patients with metastatic renal cell carcinoma (RCC).

Standard

A phase I study of recombinant human interleukin-21 (rIL-21) in combination with sunitinib in patients with metastatic renal cell carcinoma (RCC). / Grünwald, Viktor; Desar, Ingrid M E; Haanen, John; Fiedler, Walter; Mouritzen, Ulrik; Olsen, M W Brændholt; Herpen, van; Carla, M L.

In: ACTA ONCOL, Vol. 50, No. 1, 1, 2011, p. 121-126.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Grünwald, V, Desar, IME, Haanen, J, Fiedler, W, Mouritzen, U, Olsen, MWB, Herpen, V & Carla, ML 2011, 'A phase I study of recombinant human interleukin-21 (rIL-21) in combination with sunitinib in patients with metastatic renal cell carcinoma (RCC).', ACTA ONCOL, vol. 50, no. 1, 1, pp. 121-126. <http://www.ncbi.nlm.nih.gov/pubmed/21174612?dopt=Citation>

APA

Grünwald, V., Desar, I. M. E., Haanen, J., Fiedler, W., Mouritzen, U., Olsen, M. W. B., Herpen, V., & Carla, M. L. (2011). A phase I study of recombinant human interleukin-21 (rIL-21) in combination with sunitinib in patients with metastatic renal cell carcinoma (RCC). ACTA ONCOL, 50(1), 121-126. [1]. http://www.ncbi.nlm.nih.gov/pubmed/21174612?dopt=Citation

Vancouver

Grünwald V, Desar IME, Haanen J, Fiedler W, Mouritzen U, Olsen MWB et al. A phase I study of recombinant human interleukin-21 (rIL-21) in combination with sunitinib in patients with metastatic renal cell carcinoma (RCC). ACTA ONCOL. 2011;50(1):121-126. 1.

Bibtex

@article{44700ffb461342879d891198b47a2fd5,
title = "A phase I study of recombinant human interleukin-21 (rIL-21) in combination with sunitinib in patients with metastatic renal cell carcinoma (RCC).",
abstract = "sunitinib induces partial responses in 47% of patients with metastatic renal cell carcinoma (mRCC). However, the achievement of complete responses remains scarce and all patients will eventually develop progressive disease. Recombinant interleukin-21 (rIL-21) is a novel cytokine, which is believed to deliver sustained cellular anti-tumor response and the combination of both agents may work synergistically.",
keywords = "Humans, Male, Aged, Female, Middle Aged, Treatment Failure, Drug Administration Schedule, Recombinant Proteins/administration & dosage, Protein-Tyrosine Kinases/antagonists & inhibitors, Indoles/administration & dosage/adverse effects, Kidney Neoplasms/*drug therapy/pathology, Pyrroles/administration & dosage/adverse effects, Angiogenesis Inhibitors/administration & dosage/adverse effects, Antineoplastic Combined Chemotherapy Protocols/*administration & dosage/*adverse effects/pharmacokinetics, Carcinoma, Renal Cell/*drug therapy/secondary, Hematologic Diseases/chemically induced, Interleukins/administration & dosage/adverse effects, Protein Kinase Inhibitors/administration & dosage/adverse effects, Humans, Male, Aged, Female, Middle Aged, Treatment Failure, Drug Administration Schedule, Recombinant Proteins/administration & dosage, Protein-Tyrosine Kinases/antagonists & inhibitors, Indoles/administration & dosage/adverse effects, Kidney Neoplasms/*drug therapy/pathology, Pyrroles/administration & dosage/adverse effects, Angiogenesis Inhibitors/administration & dosage/adverse effects, Antineoplastic Combined Chemotherapy Protocols/*administration & dosage/*adverse effects/pharmacokinetics, Carcinoma, Renal Cell/*drug therapy/secondary, Hematologic Diseases/chemically induced, Interleukins/administration & dosage/adverse effects, Protein Kinase Inhibitors/administration & dosage/adverse effects",
author = "Viktor Gr{\"u}nwald and Desar, {Ingrid M E} and John Haanen and Walter Fiedler and Ulrik Mouritzen and Olsen, {M W Br{\ae}ndholt} and van Herpen and Carla, {M L}",
year = "2011",
language = "English",
volume = "50",
pages = "121--126",
journal = "ACTA ONCOL",
issn = "0284-186X",
publisher = "informa healthcare",
number = "1",

}

RIS

TY - JOUR

T1 - A phase I study of recombinant human interleukin-21 (rIL-21) in combination with sunitinib in patients with metastatic renal cell carcinoma (RCC).

AU - Grünwald, Viktor

AU - Desar, Ingrid M E

AU - Haanen, John

AU - Fiedler, Walter

AU - Mouritzen, Ulrik

AU - Olsen, M W Brændholt

AU - Herpen, van

AU - Carla, M L

PY - 2011

Y1 - 2011

N2 - sunitinib induces partial responses in 47% of patients with metastatic renal cell carcinoma (mRCC). However, the achievement of complete responses remains scarce and all patients will eventually develop progressive disease. Recombinant interleukin-21 (rIL-21) is a novel cytokine, which is believed to deliver sustained cellular anti-tumor response and the combination of both agents may work synergistically.

AB - sunitinib induces partial responses in 47% of patients with metastatic renal cell carcinoma (mRCC). However, the achievement of complete responses remains scarce and all patients will eventually develop progressive disease. Recombinant interleukin-21 (rIL-21) is a novel cytokine, which is believed to deliver sustained cellular anti-tumor response and the combination of both agents may work synergistically.

KW - Humans

KW - Male

KW - Aged

KW - Female

KW - Middle Aged

KW - Treatment Failure

KW - Drug Administration Schedule

KW - Recombinant Proteins/administration & dosage

KW - Protein-Tyrosine Kinases/antagonists & inhibitors

KW - Indoles/administration & dosage/adverse effects

KW - Kidney Neoplasms/drug therapy/pathology

KW - Pyrroles/administration & dosage/adverse effects

KW - Angiogenesis Inhibitors/administration & dosage/adverse effects

KW - Antineoplastic Combined Chemotherapy Protocols/administration & dosage/adverse effects/pharmacokinetics

KW - Carcinoma, Renal Cell/drug therapy/secondary

KW - Hematologic Diseases/chemically induced

KW - Interleukins/administration & dosage/adverse effects

KW - Protein Kinase Inhibitors/administration & dosage/adverse effects

KW - Humans

KW - Male

KW - Aged

KW - Female

KW - Middle Aged

KW - Treatment Failure

KW - Drug Administration Schedule

KW - Recombinant Proteins/administration & dosage

KW - Protein-Tyrosine Kinases/antagonists & inhibitors

KW - Indoles/administration & dosage/adverse effects

KW - Kidney Neoplasms/drug therapy/pathology

KW - Pyrroles/administration & dosage/adverse effects

KW - Angiogenesis Inhibitors/administration & dosage/adverse effects

KW - Antineoplastic Combined Chemotherapy Protocols/administration & dosage/adverse effects/pharmacokinetics

KW - Carcinoma, Renal Cell/drug therapy/secondary

KW - Hematologic Diseases/chemically induced

KW - Interleukins/administration & dosage/adverse effects

KW - Protein Kinase Inhibitors/administration & dosage/adverse effects

M3 - SCORING: Journal article

VL - 50

SP - 121

EP - 126

JO - ACTA ONCOL

JF - ACTA ONCOL

SN - 0284-186X

IS - 1

M1 - 1

ER -